English | 简体中文 | 繁體中文 | 한국어
Share:
Esperite (ESP) announces that Genoma SA filed appeal to the decision ruled by the Swiss Court

Genoma has filed appeal to the decision of liquidation taken on May 4th 2017. Genoma considers this decision arbitrary due to the circumstances of the commercial and legal relationship with Premaitha.

Zutphen, The Netherlands, 19 May 2017

Genoma has concluded with Premaitha an agreement in March 15th 2015 for the supply of the genetic test Iona. The implementation of this contract implied significant investment specifically related to the use of the IONA Kits. Genoma represented 65% of Premaitha's business in 2015/16.

Genoma was forced to discontinue using the Premaitha Iona test some weeks after the serious legal claim against Premaitha's technology by Illumina (Patent Infringement). Premaitha has not been able to demonstrate that the Iona test doesn't infringe Illumina's patents.

Genoma blocked payments to Premaitha, a total of +€900k for several reasons:

  • A considerable amount has been claimed for failure in the supply;
  • Illumina sued Genoma for patent infringement because of the use of Premaitha's Iona;
  • Premaitha never offered valid support for defence despite they were selling a patent infringing product.

The British supplier sent several summons for payment and finally obtained a court decision ruling for the bankruptcy of Genoma officially on May 4th 2017. The official register was updated on the 9th of May 2017.

About ESPERITE
ESPERITE Group, listed at Euronext Amsterdam and Paris, is a leading international company in regenerative and predictive medicine established in 2000.

To learn more about ESPERITE Group, or to book an interview with CEO Frederic Amar: +31 575 548 998 - ir@esperite.com or visit the websites at
www.esperite.com and www.genoma.com.




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Esperite N.V. via Globenewswire

Copyright © Thomson Reuters 2017. All rights reserved.
 Subscribe RSS Feed  
Press Releases
Nordic American Tankers Limited (NYSE:NAT) - Renewal and Filing of Shelf Registration Statement  
June 23, 2017 18:58 ET
NEJM publishes full analysis of Rydapt® (midostaurin) Phase III RATIFY trial in newly diagnosed FLT3-mutated acute myeloid leukemia (AML)  
June 23, 2017 18:00 ET
Novo Nordisk reports up to 13.8% weight loss in people with obesity receiving semaglutide in phase 2 trial  
June 23, 2017 16:45 ET
Novo Nordisk A/S: CHMP adopts positive opinion for EU label update of Victoza® based on the LEADER trial  
June 23, 2017 13:40 ET
Medtronic Announces 7 Percent Increase in Cash Dividend  
June 23, 2017 12:45 ET
Sequa Petroleum N.V. Funding Update  
June 21, 2017 00:03 ET
AIR Worldwide Releases Updated Earthquake Model for the United States  
June 19, 2017 18:13 ET
Schrader Cellars Entrusts Constellation Brands with Highly-Coveted, Critically-Acclaimed Wine Portfolio  
June 17, 2017 04:33 ET
Kymab Group Ltd: Kymab appoints Dr Martin Nicklasson as Non-Executive Chair  
June 16, 2017 16:03 ET
NANOBIOTIX : new translational data presented at ASTRO, NCI AND SITC'S Immunotherapy Workshop  
June 16, 2017 03:53 ET
More News >>
Copyright © 2017 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 10 8405 3688 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 5791 1818

Connect With us: